相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2002
已完成
4
80.0%
招募中
1
20.0%
暂无批准数据
- Mezzion Pharmaceuticals completed strategic financing from institutional investors to support its ongoing global Phase 3 FUEL-2 trial evaluating udenafil in Fontan circulation patients. - The financing will advance development of JURVIGO (udenafil) as a potential first-in-class therapy for single ventricle congenital heart disease, addressing a significant unmet medical need. - Currently no approved therapies exist specifically indicated for Fontan patients, making this a critical development for an underserved rare disease population. - The FUEL-2 trial is being conducted across leading pediatric congenital heart centers internationally with continued enrollment momentum and operational progress.
- Mezzion Pharma secured approximately $20 million in strategic funding led by Midas-Meritz New Technology Finance Association to support the ongoing global Phase 3 FUEL-2 trial of udenafil for Fontan circulation patients. - The investment represents strong institutional confidence in Mezzion's late-stage pipeline, with lead investor Midas PE citing positive FUEL-1 results and expressing belief in udenafil's potential for successful Phase 3 completion and regulatory approval. - The financing follows growing clinical momentum, including the introduction of dedicated ICD-10 codes for Fontan-associated conditions, marking progress in addressing this long-overlooked rare congenital heart disease population. - Mezzion reports accelerating enrollment and growing engagement across clinical sites for the FUEL-2 trial, with plans to continue seeking additional investments to support global development efforts.
